HDL cholesterol and ASCVD risk stratification: A debate

Atherosclerosis

Volumn 283, Issue , 2019, Pages 7-12

  Barter, Philip ^a   Genest, Jacques ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; BIOLOGICAL MARKER;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; CORONARY ARTERY ATHEROSCLEROSIS; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULARIZATION; ATHEROSCLEROSIS; BLOOD; CORONARY ARTERY DISEASE; GLOBAL HEALTH; MORBIDITY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ATHEROSCLEROSIS; BIOMARKERS; CHOLESTEROL, HDL; CORONARY DISEASE; GLOBAL HEALTH; HUMANS; MORBIDITY; RISK ASSESSMENT; RISK FACTORS;

EID: 85061387281     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2019.01.001     Document Type: Review

References (71)

1. Enger, S.C., Hjermann, I., Foss, O.P., Helgeland, A., Holme, I., Leren, P., et al. High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery 5:2 (1979), 170–181.
2. Gordon, D.J., Knoke, J., Probstfield, J.L., Superko, R., Tyroler, H.A., High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Circulation 74:6 (1986), 1217–1225.
3. Gordon, D.J., Probstfield, J.L., Garrison, R.J., Neaton, J.D., Castelli, W.P., Knoke, J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:1 (1989), 8–15.
4. Miller, M., Seidler, A., Kwiterovich, P.O., Pearson, T.A., Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol. Circulation 86:4 (1992), 1165–1170.
5. Miller, N.E., Thelle, D.S., Forde, O.H., Mjos, O.D., The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1:8019 (1977), 965–968.
6. Pekkanen, J., Linn, S., Heiss, G., Suchindran, C.M., Leon, A., Rifkind, B.M., et al. Ten- year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N. Engl. J. Med. 322:24 (1990), 1700–1707.
7. Jacobs, D.R. Jr., Mebane, I.L., Bangdiwala, S.I., Criqui, M.H., Tyroler, H.A., High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am. J. Epidemiol. 131:1 (1990), 32–47.
8. Pedersen, T.R., Olsson, A.G., Faergeman, O., Kjekshus, J., Wedel, H., Berg, K., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97:15 (1998), 1453–1460.
9. Sacks, F.M., Tonkin, A.M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C.M., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102:16 (2000), 1893–1900.
10. Simes, R.J., Marschner, I.C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R.A., et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 105:10 (2002), 1162–1169.
11. Barter, P., Gotto, A.M., LaRosa, J.C., Maroni, J., Szarek, M., Grundy, S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357:13 (2007), 1301–1310.
12. Emerging Risk Factors Collaboration, Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K.K., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302(18), 2009 Nov 11 1993-200.
13. Badimon, J.J., Badimon, L., Fuster, V., Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85:4 (1990), 1234–1241.
14. Paszty, C., Maeda, N., Verstuyft, J., Rubin, E.M., Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94:2 (1994), 899–903.
15. Rubin, E.M., Krauss, R.M., Spangler, E.A., Verstuyft, J.G., Clift, S.M., Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353:6341 (1991), 265–267.
16. Plump, A.S., Scott, C.J., Breslow, J.L., Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 91:20 (1994), 9607–9611.
17. Voight, B.F., Peloso, G.M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:9841 (2012 Aug 11), 572–580.
18. Duffy, D., Rader, D.J., Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113:8 (2006), 1140–1150.
19. Barter, P.J., Nicholls, S., Rye, K.A., Anantharamaiah, G.M., Navab, M., Fogelman, A.M., Antiinflammatory properties of HDL. Circ. Res. 95:8 (2004), 764–772.
20. Cockerill, G.W., Rye, K.A., Gamble, J.R., Vadas, M.A., Barter, P.J., High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15:11 (1995), 1987–1994.
21. Mineo, C., Deguchi, H., Griffin, J.H., Shaul, P.W., Endothelial and antithrombotic actions of HDL. Circ. Res. 98:11 (2006), 1352–1364.
22. Bisoendial, R.J., Hovingh, G.K., Levels, J.H., Lerch, P.G., Andresen, I., Hayden, M.R., et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107:23 (2003), 2944–2948.
23. Seetharam, D., Mineo, C., Gormley, A.K., Gibson, L.L., Vongpatanasin, W., Chambliss, K.L., et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res. 98:1 (2006), 63–72.
24. Tso, C., Martinic, G., Fan, W.H., Rogers, C., Rye, K.A., Barter, P.J., High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol. 26:5 (2006), 1144–1149.
25. 25Sumi, M., Sata, M., Miura, S., Rye, K.A., Toya, N., Kanaoka, Y., et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27:4 (2007), 813–818.
26. Yvan-Charvet, L., Pagler, T., Gautier, E.L., Avagyan, S., Siry, R.L., Han, S., et al. ATP- binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328:5986 (2010), 1689–1693.
27. Drew, B.G., Duffy, S.J., Formosa, M.F., Natoli, A.K., Henstridge, D.C., Penfold, S.A., et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119:15 (2009), 2103–2111.
28. Drew, B.G., Rye, K.A., Duffy, S.J., Barter, P., Kingwell, B.A., The emerging role of HDL in glucose metabolism. Nat. Rev. Endocrinol. 8:4 (2012), 237–245.
29. Rye, K.A., Barter, P.J., Formation and metabolism of prebeta-migrating, lipid- poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 24:3 (2004), 421–428.
30. Rye, K.A., Barter, P.J., Cardioprotective functions of HDLs. J. Lipid Res. 55:2 (2014), 168–179.
31. Rosenson, R.S., Brewer, H.B. Jr., Ansell, B.J., Barter, P., Chapman, M.J., Heinecke, J.W., et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 13:1 (2016), 48–60.
32. Patel, S., Di Bartolo, B.A., Nakhla, S., et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis 212:2 (2010 Oct), 392–397.
33. Duverger, N., Kruth, H., Emmanuel, F., Caillaud, J.M., Viglietta, C., Castro, G., et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 94:4 (1996), 713–717.
34. Sugano, M., Makino, N., Sawada, S., Otsuka, S., Watanabe, M., Okamoto, H., et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273:9 (1998), 5033–5036.
35. Rittershaus, C.W., Miller, D.P., Thomas, L.J., Picard, M.D., Honan, C.M., Emmett, C.D., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20:9 (2000), 2106–2112.
36. Liaw, Y.W., Lin, C.Y., Lai, Y.S., Yang, T.C., Wang, C.J., Whang-Peng, J., et al. A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit. PLoS One, 9(12), 2014, e111529.
37. 36Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., Shinkai, H., A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:6792 (2000), 203–207.
38. 37Morehouse, L.A., Sugarman, E.D., Bourassa, P.A., Sand, T.M., Zimetti, F., Gao, F., et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet- induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48:6 (2007), 1263–1272.
39. Nissen, S.E., Tsunoda, T., Tuzcu, E.M., Schoenhagen, P., Cooper, C.J., Yasin, M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:17 (2003), 2292–2300.
40. Canner, P.L., Berge, K.G., Wenger, N.K., Stamler, J., Friedman, L., Prineas, R.J., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8:6 (1986), 1245–1255.
41. Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365:24 (2011), 2255–2267.
42. Landray, M.J., Haynes, R., Hopewell, J.C., Parish, S., Aung, T., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371:3 (2014), 203–212.
43. Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J., Komajda, M., et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357:21 (2007), 2109–2122.
44. Schwartz, G.G., Olsson, A.G., Abt, M., Ballantyne, C.M., Barter, P.J., Brumm, J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367:22 (2012), 2089–2099.
45. Lincoff, A.M., Nicholls, S.J., Riesmeyer, J.S., Barter, P.J., Brewer, H.B., Fox, K.A.A., et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N. Engl. J. Med. 376:20 (2017), 1933–1942.
46. Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D.M., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121:7 (2011), 2693–2708.
47. Bowman, L., Hopewell, J.C., Chen, F., Wallendszus, K., Stevens, W., et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. 377:13 (2017), 1217–1227.
48. Madsen, C.M., Varbo, A., Nordestgaard, B.G., Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur. Heart J. 38:32 (2017), 2478–2486.
49. Luscher, T.F., Landmesser, U., von Eckardstein, A., Fogelman, A.M., High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ. Res. 114:1 (2014), 171–182.
50. Shah, A.S., Tan, L., Long, J.L., Davidson, W.S., Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54:10 (2013), 2575–2585.
51. Kontush, A., Lhomme, M., Chapman, M.J., Unraveling the complexities of the HDL lipidome. J. Lipid Res. 54:11 (2013), 2950–2963.
52. Canfran-Duque, A., Lin, C.S., Goedeke, L., Suarez, Y., Fernandez-Hernando, C., Micro-RNAs and high-density lipoprotein metabolism. Arterioscler. Thromb. Vasc. Biol. 36:6 (2016), 1076–1084.
53. Khera, A.V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M.F., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364:2 (2011 Jan 13), 127–135.
54. Rohatgi, A., Khera, A., Berry, J.D., Givens, E.G., Ayers, C.R., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 371:25 (2014 Dec 18), 2383–2393.
55. Khera, A.V., Demler, O., Adelman, S.J., Collins, H.L., Glynn, R.J., et al. Cholesterol efflux capacity, HDL particle number, and incident cardiovascular events. An analysis from the JUPITER trial (Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation 135:25 (2017 Apr 27), 2494–2504.
56. DiDonato, J.A., Huang, Y., Aulak, K.S., Even-Or, O., Gerstenecker, G., et al. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation 128:15 (2013), 1644–1655.
57. Huang, Y., DiDonato, J.A., Levison, B.S., Schmitt, D., Li, L., Wu, Y., Buffa, J., Kim, T., Gerstenecker, G.S., Gu, X., et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20:2 (2014), 193–203.
58. Genest, J., Choi, H.Y., Novel approaches for HDL-directed therapies. Curr. Atheroscler. Rep., 19(12), 2017 Nov 4, 55.
59. Ko, D.T., Alter, D.A., Guo, H., Koh, M., Lau, G., et al. High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study. J. Am. Coll. Cardiol. 68:19 (2016 Nov 8), 2073–2083.
60. Boekholdt, S.M., Arsenault, B.J., Hovingh, G.K., Mora, S., Pedersen, T.R., et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 128:14 (2013 Oct 1), 1504–1512.
61. Bowe, B., Xie, Y., Xian, H., Balasubramanian, S., Zayed, M.A., Al-Aly, Z., High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. Veterans. Clin. J. Am. Soc. Nephrol. 11:10 (2016 Oct 7), 1784–1793.
62. Ridker, P.M., Genest, J., Boekholdt, S.M., Libby, P., Gotto, A.M., et al. JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376:9738 (2010 Jul 31), 333–339.
63. Mortensen, M.B., Afzal, S., Nordestgaard, B.G., Falk, E., The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study. Eur. Heart J. 36:36 (2015 Sep 21), 2446–2453.
64. Frikke-Schmidt, R., Nordestgaard, B.G., Stene, M.C., Sethi, A.A., Remaley, A.T., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299:21 (2008), 2524–2532.
65. Holmes, M.V., Asselbergs, F.W., Palmer, T.M., Drenos, F., Lanktree, M.B., et al. Mendelian randomization of blood lipids for coronary heart disease. Eur. Heart J. 36:9 (2015 Mar 1), 539–550.
66. Geller, A.S., Polisecki, E.Y., Diffenderfer, M.R., Asztalos, B.F., Karathanasis, S.K., et al. Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. J. Lipid Res. 59:12 (2018 Dec), 2421–2435.
67. Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375:9729 (2010), 1875–1884.
68. Lincoff, A.M., Tardif, J.C., Schwartz, G.G., Nicholls, S.J., Rydén, L., et al. AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 311:15 (2014 Apr 16), 1515–1525.
69. Keene, D., Price, C., Shun-Shin, M.J., Francis, D.P., Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ, 349, 2014, g4379.
70. Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. U. S. A. 110:49 (2013), 19754–19759.
71. Choi, H., Ruel, I., Malina, A., Garrod, D.R., Oda, M., et al. Desmocollin 1 is abundantly expressed in atherosclerosis and impairs HDL biogenesis. Eur. Heart J. 39:14 (2018 Apr 7), 1194–1202.